{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-068745","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.834733+00:00","generated_at":"2026-06-22T14:42:27.400848+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INmune Bio Q3 net loss $7.7M; FDA clinical hold on XPro AD trials ongoing","bullets":["Net loss Q3 2022 ~$7.7M vs $9.5M Q3 2021; R&D $5.2M, G&A $2.4M.","Cash & equivalents ~$57.4M at Sept 30, 2022; ~17.9M shares outstanding.","FDA clinical hold on XPro1595 AD trials; company addressed CMC query; discussions ongoing.","INKmune shows positive solid tumor data; 2nd UK site Nov 2022; pre-IND with FDA for solid tumor.","Upcoming: XPro Phase 2 AD/TRD after hold lifted; INKmune solid tumor 1H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-068745","json":"https://secwatch.observer/filing/0001213900-22-068745.json","markdown":"https://secwatch.observer/filing/0001213900-22-068745.md","text":"https://secwatch.observer/filing/0001213900-22-068745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390022068745/0001213900-22-068745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390022068745/ea167968-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T14:42:27.400848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c843247eded8c95e14cea2f8d9d87bcdbb713ac","claim":"Inmune Bio, Inc. reported the quarter ended September 30, 2022 results: net income approximately $7.7 million.","evidence_excerpt":"Net loss attributable to common stockholders for the quarter ended September 30, 2022 was approximately $7.7 million, compared to approximately $9.5 million for the quarter ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390022068745/0001213900-22-068745-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"approximately $7.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}